COMP <GO>
ENLV vs MDCX // RSI-14 & 200D SMA MOMENTUM
Enlivex Ltd. (NASDAQ) VS. Medicus Pharma Ltd. (NASDAQ) • 15-METRIC TALLY: ENLV 3
— MDCX 1
▲ RSI-14 & 200D SMA MOMENTUM LEADER: ENLV
LAST: $2.54 (-2.68%) • MKT CAP: $3.9M
rsi-technicals
65.3
LAST: $2.15 (-13.31%) • MKT CAP: $4.1M
rsi-technicals
16.6
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ENLV VS. MDCX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ENLV | MDCX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -0.60% | -35.00% | +34.40 | ENLV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 1/9 | +2.00 | ENLV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 65.3 | 16.6 | +48.70 | ENLV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.9M | $4.1M | -$176.2K | MDCX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ENLV REV | MDCX REV | ENLV GROSS % | MDCX GROSS % | ENLV FCF | MDCX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$10.5M | -$22.8M |
| FY 2024 | $0 | $0 | — | — | -$13.1M | -$10.2M |
| FY 2023 | $0 | $0 | — | — | -$23.5M | -$4.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ENLV // BETA —
MDCX // BETA —